New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
08:09 EDTCLVSClovis volatility expected to move on receiving FDA Breakthrough Therapy
Clovis Oncology volatility is expected to move after the FDA grants Breakthrough Therapy designation for CO-1686. Overall option implied volatility of 88 is above its 26-week average of 72 according to Track Data suggesting larger near term price movement.
News For CLVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for CLVS

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use